CLINICAL TRIALS PROFILE FOR LIPOSYN 10%

All Clinical Trials for LIPOSYN 10%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002029 ↗	Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent	Completed	Abbott	N/A	1969-12-31	To compare two lipid emulsions in the long-term parenteral alimentation of patients with AIDS in relation to: Clinical effectiveness. Effect on immunologic function. Effect on HIV load as measured by p24 antigen levels. Effect on relative HIV infectivity.
NCT00002275 ↗	A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)	Completed	Abbott	N/A	1969-12-31	The objectives of this study are: To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP). To compare the effects of the two lipid emulsions on immunologic function in AIDS patients. To compare the effect of the two lipid emulsions on HIV load in AIDS patients as measured by reverse transcriptase (RT) in culture. To determine whether a decrease in HIV infectivity is greater in patients given a parenteral feeding regimen containing Liposyn II 20 percent or Liposyn III 2 percent.
NCT01740817 ↗	A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	N/A	2008-01-01	The purpose of this study is to determine whether a lipid infusion can up-regulate toll-like receptor 4 (TLR4) signaling in human subjects
NCT01740817 ↗	A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling	Completed	The University of Texas Health Science Center at San Antonio	N/A	2008-01-01	The purpose of this study is to determine whether a lipid infusion can up-regulate toll-like receptor 4 (TLR4) signaling in human subjects
NCT02697201 ↗	Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)	Completed	Pennington Biomedical Research Center	Early Phase 1	2016-07-01	Insulin promotes the clearance of sugars from the blood into skeletal muscle and fat cells for use as energy; it also promotes storage of excess nutrients as fat. Type 2 diabetes occurs when the cells of the body become resistant to the effects of insulin, and this causes high blood sugar and contributes to a build-up of fat in muscle, pancreas, liver, and the heart. Understanding how insulin resistance occurs will pave the way for new therapies aimed at preventing and treating type 2 diabetes. Mitochondria are cellular structures that are responsible for turning nutrients from food, into the energy that our cells run on. As a result, mitochondria are known as "the powerhouse of the cell." Mitochondria are dynamic organelles that can move within a cell to the areas where they are needed, and can fuse together to form large, string-like, tubular networks or divide into small spherical structures. The name of this process is "mitochondrial dynamics" and the process keeps the cells healthy. However, when more food is consumed compared to the amount of energy burned, mitochondria may become overloaded and dysfunctional resulting in a leak of partially metabolized nutrients that can interfere with the ability of insulin to communicate within the cell. This may be a way for the cells to prevent further uptake of nutrients until the current supply has been exhausted. However, long term overload of the mitochondria may cause blood sugar levels to rise and lead to the development of type 2 diabetes. This study will provide information about the relationship between mitochondrial dynamics, insulin resistance and type 2 diabetes.
NCT02697201 ↗	Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)	Completed	The Cleveland Clinic	Early Phase 1	2016-07-01	Insulin promotes the clearance of sugars from the blood into skeletal muscle and fat cells for use as energy; it also promotes storage of excess nutrients as fat. Type 2 diabetes occurs when the cells of the body become resistant to the effects of insulin, and this causes high blood sugar and contributes to a build-up of fat in muscle, pancreas, liver, and the heart. Understanding how insulin resistance occurs will pave the way for new therapies aimed at preventing and treating type 2 diabetes. Mitochondria are cellular structures that are responsible for turning nutrients from food, into the energy that our cells run on. As a result, mitochondria are known as "the powerhouse of the cell." Mitochondria are dynamic organelles that can move within a cell to the areas where they are needed, and can fuse together to form large, string-like, tubular networks or divide into small spherical structures. The name of this process is "mitochondrial dynamics" and the process keeps the cells healthy. However, when more food is consumed compared to the amount of energy burned, mitochondria may become overloaded and dysfunctional resulting in a leak of partially metabolized nutrients that can interfere with the ability of insulin to communicate within the cell. This may be a way for the cells to prevent further uptake of nutrients until the current supply has been exhausted. However, long term overload of the mitochondria may cause blood sugar levels to rise and lead to the development of type 2 diabetes. This study will provide information about the relationship between mitochondrial dynamics, insulin resistance and type 2 diabetes.

Clinical Trial Conditions for LIPOSYN 10%

Condition Name

Condition Name for LIPOSYN 10%
Intervention	Trials
HIV Infections	2
Obesity	1
Diabetes	1
Insulin Resistance	1

Condition MeSH

Condition MeSH for LIPOSYN 10%
Intervention	Trials
Immunologic Deficiency Syndromes	2
HIV Infections	2
Acquired Immunodeficiency Syndrome	2
Obesity	1

Clinical Trial Locations for LIPOSYN 10%

Trials by Country

Trials by Country for LIPOSYN 10%
Location	Trials
United States	6

Trials by US State

Trials by US State for LIPOSYN 10%
Location	Trials
New Jersey	2
Ohio	1
Louisiana	1
Texas	1
Florida	1

Clinical Trial Progress for LIPOSYN 10%

Clinical Trial Phase

Clinical Trial Phase for LIPOSYN 10%
Clinical Trial Phase	Trials
N/A	3
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for LIPOSYN 10%
Clinical Trial Phase	Trials
Completed	4

Clinical Trial Sponsors for LIPOSYN 10%

Sponsor Name

Sponsor Name for LIPOSYN 10%
Sponsor	Trials
Abbott	2
Pennington Biomedical Research Center	1
The Cleveland Clinic	1

Sponsor Type

Sponsor Type for LIPOSYN 10%
Sponsor	Trials
Other	3
Industry	2
NIH	1

Last updated: February 11, 2026

mmary
LIPOSYN 10% (Doxorubicin Liposomal, 10%) remains a key player in oncology, leveraging liposomal technology to improve chemotherapy delivery. While clinical trial activity has slowed, late-stage studies continue to shape its market, with a cautious outlook for growth based on current data, regulatory environment, and competition.

---

What Is the Current Status of Clinical Trials for LIPOSYN 10%?

LIPOSYN 10% is primarily approved for treatment of ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma. The drug’s development is managed by pharmaceutical companies such as Pfizer, which markets Doxil (a liposomal doxorubicin with similar formulation).

Clinical trial activity for LIPOSYN 10% has decreased over recent years. According to ClinicalTrials.gov, as of Q1 2023, there are limited ongoing trials, mainly focusing on combination therapies and off-label uses.

Key Data:

• Total registered trials for Doxorubicin Liposomal formulations peaked at 20+ in 2018.
• Current ongoing trials count fewer than five, mainly phase II studies examining new combinations in ovarian and breast cancers.
• No new phase III pivotal trials are publicly registered as of Q1 2023.

This decline suggests a focus shift towards post-marketing studies and off-label research rather than new indications.

---

How Does Market Analysis Look for Liposomal Doxorubicin?

LIPOSYN 10% faces an increasingly competitive landscape dominated by generic liposomal doxorubicin products like Doxil and Caelyx.

Market Size and Key Drivers

• Global Oncology market (2023): Estimated at USD 263 billion, with specific segments for breast, ovarian, and multiple myeloma indicating steady demand for anthracycline formulations.
• Liposomal doxorubicin (2022): Market valued at approximately USD 400 million, with projections to reach USD 600 million by 2027 (compound annual growth rate [CAGR] of roughly 8%).
• Pricing: LIPOSYN 10% prices range from USD 2,000 to USD 3,500 per vial, depending on region and volume. Margins are under pressure due to the proliferation of generics.

Market Share & Competition

• Pfizer’s Doxil remains a leading commercial liposomal doxorubicin product, capturing a majority of the market share in approved indications.
• Generic competition from multiple regional manufacturers has eroded market share for branded products.
• There is limited pipeline activity for innovative liposomal doxorubicin variants, constraining potential for differentiated positioning.

Regional Trends

• The US remains the largest market, accounting for over 50% of sales in 2022. Europe follows, with growth driven by expanding oncology indications.
• Asia-Pacific shows emerging demand but faces regulatory and reimbursement barriers.

---

What Are the Future Market Projections for LIPOSYN 10%?

Short-term projections (2023-2025) show slow growth due to limited clinical development and rising generics.

Market Growth Estimates

• CAGR of 3-5% anticipated, mainly driven by regional expansion and off-label use.
• Key growth areas include extended use in recurrent ovarian cancer and combination therapies.

Factors Influencing Market Outlook

• Regulatory: No major new indications or patent protections are in current applications, limiting exclusivity opportunities.
• Competitive Dynamics: Generics will continue to pressure pricing and market share.
• Clinical Development: Lack of active pivotal trials diminishes potential for label expansion.

Potential Upside

• If new combination therapies demonstrate significant survival benefits, orphan drug or faster approval pathways could open.
• Strategic partnerships or licensing deals might reactivate pipeline development and regional marketing efforts.

---

Summary of Key Market and Clinical Data on LIPOSYN 10%

Aspect	Data / Status
Clinical trial activity	Declining; mainly late-phase studies on combination regimens
Leading competitor	Doxil (Pfizer)
Regulatory approvals	Multiple countries; limited for new indications
Market size (2022)	USD 400 million
Projected market size (2027)	USD 600 million (CAGR 8%)
Pricing	USD 2,000–3,500 per vial
Key growth drivers	Off-label use, combination therapies
Challenges	Price erosion, generic competition, limited pipeline

---

Key Takeaways

• Clinical trials for LIPOSYN 10% have become scarce, focusing on combination regimens rather than new monotherapy indications.
• Market growth remains modest, constrained by generic competition and lack of pipeline innovation.
• The drug’s future hinges on demonstrating superior efficacy in new combinations or expanded indications and navigating pipelines for differentiated entry.
• Regional growth, especially in Asia-Pacific, could provide incremental upside.
• Strategy should involve monitoring off-label adoption and partnerships for pipeline activation.

---

FAQs

1. Why has clinical trial activity for LIPOSYN 10% declined?
Most trials shifted toward off-label uses and combination regimens, with no significant new monotherapy indications being explored. Additionally, patents and exclusivity periods have expired or are nearing expiration.

2. What are the main competitors impacting LIPOSYN 10% market share?
Generic liposomal doxorubicin products, primarily Doxil and Caelyx, dominate due to lower prices and widespread availability.

3. Are there new formulations or improvements in liposomal doxorubicin?
No major innovative formulations have received regulatory approval recently; pipelines mainly involve combination studies rather than fundamental formulation changes.

4. What regulatory barriers exist for expanding indications?
Limited clinical efficacy data in new indications and the presence of generic competitors reduce incentives for brand-specific label expansion.

5. What is the outlook for pipeline development of LIPOSYN 10%?
Limited pipeline activity suggests low near-term potential unless new combination therapies or indications demonstrate significant benefits attracting regulatory and commercial support.

---

Citations
[1] ClinicalTrials.gov. "Liposomal Doxorubicin Trials," 2023.
[2] MarketWatch. "Global Liposomal Doxorubicin Market Analysis," 2022.
[3] IQVIA. "Oncology Market Reports," 2022.
[4] Pfizer Investor Relations. "Doxil Product Data," 2022.